Clinical effectiveness of the probiotic containing B. longum, B. breve, L. rhamnosus, L. acidophilus in the treatment of irritable bowel syndrome with diarrhea

The study was devoted to evaluating the effectiveness of the probiotic product containing strains of Bifidobacterium longum, Bifidobacterium breve, Lactobacillus rhamnosus, Lactobacillus acidophilus as part of complex therapy of irritable bowel syndrome with diarrhea (IBS-D). Material and methods. 30 patients (average age 35,2±8,7 years) with IBS-D were examined. In the observed patients, the severity of abdominal pain, flatulence, and stool characteristics were assessed. Feces were cultured for dysbacteriosis and opportunistic flora, depression and anxiety were screened, cognitive function and quality of life was studied. In addition to standard therapy, the patients received the product containing lyophilized probiotic microorganisms (B. longum, B. breve, L. rhamnosus and L. acidophilus 3,9 billion microorganisms in 1 capsule) 1 capsule per day with meals for a period of 8 weeks. Results and conclusion. During therapy with the use of the probiotic in patients with IBS-D, the intensity of abdominal pain, assessed using VAS, significantly decreased from 3,5±1,4 to 1,7±1,2 points, the frequency of stools decreased (from 3,3±0,6 to 1,6±0,3), the type of stool changed (from 5,8±1,2 to 3, 1 ± 1,2). A complete regression of flatulence was found in 36,7% of patients, the frequency of significantly pronounced flatulence decreased significantly from 20 to 3,3%, moderately severe - from 46,7 to 20%. As a result of treatment, an increase in the content of typical E. coli (from 5,3±1,5 to 7,8±0,8 lg CFU/g), bifidobacteria (from 5,6±1,2 to 8,1±1,2 lg CFU/g), lactobacilli (from 5,5±0,8 to 7,5±0,9 lg CFU/g), elimination of opportunistic enterobacteria, hemolytic E. coli, fungi of the genus Candida. A significant decrease in the level of anxiety from 5,9±1,9 to 3,2±0,7 points according to the HADS was established. According to the MoCA, some patients (n=5; 16,7%) had 23 points or less (22,4±0,9), which indicated the presence of cognitive impairment. The treatment with the inclusion of a probiotic led to a significant increase in the index to (26,7±1,5) and regression of the identified changes. Improvement in the quality of life (questionnaire SF-36) was revealed on the scales of psychological health, emotional and role functioning.

Bifidobacterium longum, Bifidobacterium breve, Lactobacillus rhamnosus, Lactobacillus acidophilus, irritable bowel syndrome, intestinal dysbacteriosis, anxiety, cognitive disorders, probitics, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus rhamnosus, Lactobacillus acidophilus Primadophilus® Bifidus